

10TH AIS Antibody Industrial 2022 Symposium

**JUNE 28-29, 2022
MONTPELLIER, FRANCE**

PROGRAMME

Jour 1 – Le 28 juin 2022

Opening Keynotes Lectures

IONTAS



Peter Slavny
CTO and co-founder
IONTAS, UK

Clinical Trials and Translational Investigations into CAR-T Cell Therapy for Cancer

MGH MASSACHUSETTS
GENERAL HOSPITAL



Mark Leick
Instructor at Harvard Medical School and an attending physician in the
Hematopoietic Cell Transplant and Cell Therapy Division of Oncology
Massachusetts General Hospital (MGH), USA

Track IO Novel mAb target – BsAbs – Fc- fusion protein/ Rare diseases

Session I

*Avelumab internalization by human circulating
immune cells is mediated by both Fc gamma receptor
and PD-L1 binding*

MERCK



Hulin Jin
Associate Director
Merck KGaA, Germany

MERCK



Berend Neuteboom
Senior Scientific Director
Merck KGaA, Germany

Track Adoptive cell therapy & Gene Editing

Session I

*Accessible and affordable CAR-T cell production in
academia*

IDIBAPS



Manel Juan Otero
Head of Immunology Service at Hospital
Clínic de Barcelona
IDIBAPS-Hospital Clínic, Spain

KCT
Kuopio Center
for Gene and Cell Therapy



Tuula Kekarainen
Cell Therapy Unit Director
Kuopio Center for Gene and Cell Therapy
(KCT), Finland

Engineering T Cells for in vivo Secretion of Tumor- Specific T Cell-Redirecting Bispecific Antibodies

**Hospital Universitario
12 de Octubre**



Luis Alvarez-Valina
Head of the Cancer Immunotherapy Unit
Hospital Universitario "12 de Octubre", Spain

From data to predictions: AI-based virtual screening for multi-specific protein therapeutics

sanofi



Norbert Furtmann
Head of Computational & High-throughput
Engineering Large Molecule Research
Sanofi R&D, Germany

Track IO Novel mAb target – BsAbs – Fc- fusion protein/ Rare diseases

Session II

*Antibody engineering for the generation of potent NK
cell engagers via triggering NKG2D*

MERCK



Stefan Zielonka
Director, Protein Engineering & Antibody
Technologies
Merck Healthcare KGaA, Germany

PVRIG and TIGIT immune checkpoint blockade in cancer: Emerging translational data from clinical trials

compugen
FROM CODE TO CLINE™



Pierre Ferré
VP Preclinical Development
Compugen, Israel

Preclinical models to assess safety and efficacy of engineered T cells

**institut
cochin**
CENTRE DE RECHERCHE



Emmanuel Donnadieu
Group Leader
Institut Cochin, France

Track Adoptive cell therapy & Gene Editing

Session II

CAR-Macrophage Therapy

**carisma
THERAPEUTICS**



Thomas Condamine
Sr Director, Discovery & Translational
Sciences
Carisma Therapeutics, USA

IL1RAP CAR T cells development

**CanCell
Therapeutics**
Innovative Med



Christophe Ferrand
CEO co-founder
CanCell Therapeutics

Pitch Session : Innovative Approaches and New trend Technologies

Call for Abstracts until April 1st 2022

CALL for ABSTRACTS

Deadline April 1st 2022

POSTER Presentation - WINE & CHEESE - INNOVATION PITCH

Cocktail Gala Dinner

Intellectual Property : Where do we go from now ?

Patent protection beyond the antibody sequence

Mathys & Squire



Juliet Redhouse
Partner, UK & European Patent Attorney
Mathys & Squire, UK



Gala Dinner
Musée Fabre, Fine Arts Museum
39 Boulevard Bonne Nouvelle
34000 Montpellier, France

Inscription en ligne

ICI

PROGRAMME

Jour 2 – Le 29 juin 2022

Track Antibodies-based Immunotherapies : latest advancements

Session I

Engineering antibodies for immune stimulation



Mark Cragg

Professor of Experimental Cancer Biology
University Southampton, UK

Anticancer IgA-based immunotherapies



Marjolijn Van Egmond

Professor Oncology and Inflammation
Amsterdam UMC, The Netherlands

Academy and industry: discovery and development of therapeutic phage display-derived anti-Spike antibodies




Federico Bertoglio

Post-doctoral researcher
Technische Universität Braunschweig, Germany

Track New Tools & Methods to accelerate Analytical & Characterization of Biotherapeutics

Multi-level structural characterization of mAbs, ADCs, BsAbs, Fc-fusion proteins and ImmunoCytokines



Alain Beck

Senior Director, Biologics CMC & Developability
Pierre Fabre, France

Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody



Dietmar Reusch

Director Development Analytics
Roche Diagnostics GmbH, Germany



Udo Roth

Laboratory Head MS
Sanofi, Germany

Track Antibodies-based Immunotherapies : latest advancements

Session II

CALY-002, antibody inhibiting Interleukin-15 (IL-15) for treatment of several gastrointestinal indications



Alain Vicari

CEO & Co-Founder
Calypso Biotech, Switzerland



Christian Jorgensen

Director IRMB, Group Leader of the 'Mesenchymal stem Cells', coordinator of the ECellFrance & Cartigen platforms
CHRU Montpellier, France

T cell help and NK cell mediated antibody dependent cellular cytotoxicity



George Weiner

Professor/Director
Holden Comprehensive Cancer Center, Iowa University, USA

Track Complex Biologics CMC & Developability

An update on immunogenicity of therapeutic antibodies



Bernard Maillere

Head, laboratory of cellular immunology and biotechnology
CEA Saclay, France

Setting the Stage for Tolerance in Biologics Therapy



Amy Rosenberg

Senior Director of Immunology and Protein Therapeutics
EpiVax, USA

ARGX-117, an inhibitory C2 antibody with sweeping properties leading to sustained in vivo activity




Tim Delahaye

Scientist
ArgenX, Belgium

Track Driving innovative drugs into clinical success



Monalizumab, a first in class NK/T cells checkpoint inhibitor



Stéphanie Cornen

Director Program Management
Innate Pharma, France

The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response including Vγ9Vδ2 T cells and patients treatment



Daniel Olive

Chairman of Tumor Immunology CCRM and Institut Paoli Calmettes
Scientific Founder, IMTbeck, France.

cinrebafusp alfa (PRS-343), a 4-1BB/HER2 Anticlin-bispecific for the treatment of HER2-expressing gastric cancer



Shane Ollwill

Senior Vice President, Chief Development Officer
Pieris Pharmaceuticals, Germany

Track Manufacturing and bringing into the market



An agile CMC strategy and plan based on 3 Pillars to accelerate the manufacturing of the therapeutic antibodies



Olivier Favre-Bulle

CEO
3Biotech, France

Current Challenges & Opportunities on biotherapeutics manufacturing



Anthony Munn

Head of Development Services
Lonza, UK

International Nonproprietary Names (INN) for monoclonal antibodies: an evolving nomenclature system



Raffaella Balocco Mattavelli

Unit Head, International Nonproprietary Names Programme (INN) and Classification of Medical Products
World Health Organization, Switzerland

Closing Keynotes

Potency assays for bispecific antibodies against SARS-CoV-2



Baolin Zhang

Senior Investigator, Biologics CMC Leader, SBRBPAS Expert
Food And Drug Administration (FDA) USA

RNA-1944, a lipid nanoparticle-encapsulated messenger RNA encoding the heavy and light chains of a CHIKV-specific monoclonal neutralizing antibody



Allison August

Vice President, Clinical Development, Infectious Diseases
Moderna, USA